跳至主要内容
临床试验/NL-OMON36793
NL-OMON36793尚未招募不适用

Effectiveness of verapamil in patients with carbamazepine-resistant epilepsy - Verapamil in epilepsy patients

Stichting Epilepsie Instellingen Nederland0 个研究点目标入组 40 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • - patients aged 18 years and older with a history of localization-related epilepsy of at least 2 years;
  • - epilepsy not controlled despite the (previous) use of two or more antiepileptic drugs;
  • - current use of carbamazepine as an antiepileptic drug, with the possible addition of no more than one other antiepileptic drug;
  • - seizure frequency of at least 2 seizures per month;
  • - AED serum levels in therapeutic range

排除标准

  • - There was no or an uncertain diagnosis of epilepsy, based on clinical history, seizure description and/or EEG registration.
  • - progressive neurological disease
  • - cardiac disease (heart failure; 2nd or 3rd degree atrioventricular block; sick sinus syndrome; Wolf-Parkinson-White syndrome; sinus bradycardia)
  • - hypotension (defined as lower systolic pressure than 100 mm Hg and/or lower diastolic prerssure than 70 mm Hg)
  • - pregnancy

研究者

相似试验